Related Experiment Videos
Desmopressin does not reduce bleeding and transfusion requirements in congenital heart operations
W C Oliver1, P J Santrach, G K Danielson
1Department of Anesthesiology, Mayo Foundation, Rochester, Minnesota 55905, USA. oliver.william@mayo.edu
Insights
Desmopressin (DDAVP) did not reduce blood loss or transfusion needs in complex congenital heart surgery patients. This study found no benefit for prophylactic DDAVP in this specific patient population.
Area of Science:
- Cardiovascular Surgery
- Anesthesiology
- Pharmacology
Background:
- Desmopressin (DDAVP) is used to reduce blood loss in adult cardiac surgery.
- Its efficacy in complex congenital heart repair remains unproven.
- This study investigates DDAVP in pediatric and young adult complex congenital heart operations.
Purpose of the Study:
- To evaluate the effectiveness of desmopressin (DDAVP) in reducing blood loss and transfusion requirements.
- To assess the prophylactic use of DDAVP in patients undergoing complex congenital heart operations.
- To determine if DDAVP is warranted for this patient group.
Main Methods:
- Prospective, randomized, double-blind trial involving 60 patients under 40 years old.
- Patients underwent complex congenital heart operations (44 redo, 16 primary).
- Desmopressin (DDAVP) or placebo was administered post-protamine; blood loss and transfusion data were analyzed.
Main Results:
- No significant differences in demographic or surgical characteristics between groups.
- No difference in postoperative blood loss between desmopressin (DDAVP) and placebo groups.
- Transfusion requirements were also similar between the desmopressin (DDAVP) and placebo groups.
Conclusions:
- Prophylactic desmopressin (DDAVP) is not recommended for complex congenital heart operations.
- The drug did not effectively reduce excessive bleeding or the need for transfusions.
- Current evidence does not support the use of DDAVP in this surgical context.
Background:
Desmopressin (DDAVP) has been evaluated in many randomized clinical trials as a means to reduce blood loss and transfusion of allogeneic blood in cardiac operation requiring cardiopulmonary bypass. Desmopressin reduces blood loss in adult patients with excessive bleeding after cardiac operation. Its usefulness in patients undergoing complex congenital heart repair with cardiopulmonary bypass is unproved.
Methods:
Sixty patients younger than 40 years of age scheduled for complex congenital heart operation (44 redo, 16 primary) were enrolled in this prospective, randomized, double-blind trial. Desmopressin 0.3 microg/kg or placebo was administered 10 minutes after protamine administration. Transfusion requirements and postoperative blood loss were recorded. Differences were analyzed using analysis of variance with a p value of 0.05 or less used to denote statistical significance.
Results:
There were no differences in demographic or surgical characteristics between the DDAVP or placebo groups. There was no difference in blood loss and transfusion requirements between the DDAVP and placebo groups. During the intraoperative postinfusion time period, the median blood loss for redo patients was 343 versus 357 mL/m2 for placebo versus DDAVP, respectively, and for primary patients, the median blood loss was 277 versus 228 mL/m2.
Conclusions:
The prophylactic use of DDAVP to reduce excessive bleeding or transfusion requirements in patients undergoing complex congenital heart operations is not warranted.